EVEfsevia Vakiani

Efsevia Vakiani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Efsevia Vakiani has a total of 254 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.

  • Open Access

    Supplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.

  • Open Access

    Data from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.

  • Open Access

    Supplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.

  • Open Access

    Supplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Supplemental Figures with Legends.

  • Open Access

    Supplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.

  • Open Access

    Supplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.

  • Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

    by Michael B. Foote, Guilherme Harada, Somer Abdelfattah, Nil Urganci, Paolo Manca, Jinru Shia, Henry Walch, Guillem Argilés, Oliver Artz, Rona Yaeger, et al.

    Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.

  • Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma

    by Samuel L. Cytryn, Raktim Borpatragohain, Karmelina Charalambous, William Phu, Ronak Shah, Samuel Nussenzweig, Steven B. Maron, Henry Walch, Walid K. Chatila, Efsevia Vakiani, et al.

    PURPOSE: We sought to characterize the genomic landscape of gastroesophageal adenocarcinoma (GEA) using next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), compare the genomic profile to tissue NGS, and determine the association of circulating tumor DNA (ctDNA) detection with clinical outcomes. METHODS: In this prospective biospecimen-collection study (2017-2022), cfDNA was analyzed using a clinically validated 129-gene tumor-informed NGS assay Memorial Sloan Kettering-Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS); tissue-NGS was performed using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In total, 169 patients with GEA underwent baseline molecular profiling of cfDNA; 93 had localized disease, 55 had untreated metastatic disease, and 21 had progressive metastatic disease. The frequency of the most common alterations was similar between platforms, although copy-number alterations were detected less frequently in plasma than in tissue (10% v 40%; P < .001). Matched-tumor NGS was conducted in 154 patients (91%). Baseline ctDNA detection and on-treatment clearance were associated with improved overall survival and recurrence-free survival in patients with localized disease and progression-free survival in patients with metastatic disease. Baseline ctDNA detection was a stronger predictor of overall survival than American Joint Committee on Cancer (AJCC) clinical stage and positively predicted lymph node metastasis in 87% of cases. Trends in variant allele fractions correlated with pathologic responses to neoadjuvant therapy more closely than fluorodeoxyglucose-positron emission tomography standard uptake values. Persistence or resurgence of ctDNA was associated with worse survival and forecasted recurrent disease a median of 7 months sooner than imaging. CONCLUSION: cfDNA analysis using MSK-ACCESS in patients with GEA is a valuable adjunctive clinical tool that enhances molecular profiling, prognostication, treatment response assessment, and detection of recurrent disease in conjunction with tissue NGS, imaging, and AJCC clinical staging criteria.


  • Open Access

    supplementary legend1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

    by Nicolas A. Giraldo, Esther Drill, Baby A. Satravada, Imane El Dika, A. Rose Brannon, Josephine Dermawan, Abhinita Mohanty, Kerem Ozcan, Debyani Chakravarty, Ryma Benayed, et al.